rs145999145 — PLD3 V232M

PLD3 V232M — A Rare Lysosomal Variant at the Edge of Alzheimer's Genetics

Deep in the endolysosomes of every cortical and hippocampal neuron, a protein called PLD3 (phospholipase D family member 3) acts as a 5′ exonuclease — degrading single-stranded DNA and RNA that accumulates in the acidic lysosomal lumen. This housekeeping role prevents inflammatory nucleic acid signals from leaking into the cytosol and supports the orderly processing of amyloid precursor protein (APP)¹¹ amyloid precursor protein (APP)
APP is cleaved in the endolysosomal compartment; the balance between amyloidogenic (Aβ-producing) and non-amyloidogenic cleavage is influenced by lysosomal function. The rs145999145 variant (c.694G>A, p.Val232Met) substitutes methionine for valine at position 232 and is found in roughly 0.5% of Europeans — rare enough that its population-genetic signal has been difficult to replicate, yet functionally well-characterised as a loss-of-function variant.

The Mechanism

The Val232Met substitution disrupts two interconnected aspects of PLD3 biology. First, Demirev et al. (2019)²² Demirev et al. (2019)
V232M substitution restricts a distinct O-glycosylation of PLD3 and its neuroprotective function. Neurobiology of Disease, 2019 showed that V232M blocks an essential O-glycosylation at threonine 271. This modification is required for normal lysosomal trafficking; without it, PLD3 mislocalises, lysosomes enlarge abnormally, and the mutant protein loses its ability to reduce ER stress and neuronal apoptosis in Drosophila Alzheimer's models. Second, Nackenoff et al. (2021)³³ Nackenoff et al. (2021)
PLoS Genetics demonstrated directly that the V232M variant protein "lacked PLD activity" in isolated lysosomal fraction assays, confirming a genuine enzymatic loss-of-function. In 531 ROS/MAP participants, higher prefrontal PLD3 expression correlated with lower amyloid plaque burden and slower global cognitive decline (p=0.02), suggesting PLD3 activity has measurable consequences for AD trajectory.

The downstream impact on neuronal circuits was defined by Yuan et al. (2022) in Nature⁴⁴ Yuan et al. (2022) in Nature
PLD3 affects axonal spheroids and network defects in Alzheimer's disease. PLD3 accumulates in plaque-associated axonal spheroids — dystrophic axon swellings that cluster around amyloid plaques — and drives the formation of enlarged endolysosomal vesicles within them. These oversized spheroids act as electrical current sinks, producing action-potential conduction blockades proportional to their size. CRISPR deletion of PLD3 in mouse AD models reduced spheroid volume and restored axonal conduction nearly to wild-type levels, demonstrating that PLD3 dysfunction contributes to network failure through a mechanism independent of amyloid burden alone.

The Evidence

Cruchaga et al. (2013) in Nature⁵⁵ Cruchaga et al. (2013) in Nature
whole-exome sequencing of 14 AD families plus validation in 11,354 European cases and controls identified V232M as doubling AD risk (OR 2.10, 95% CI 1.47–2.99, p=2.93×10⁻⁵). The variant segregated with disease in two independent families and showed gene-level burden across all PLD3 coding variants (European OR 2.75; African American OR 5.48).

However, three replication letters published simultaneously in Nature in 2015 challenged these findings. Lambert et al. (PMID 25832408)⁶⁶ Lambert et al. (PMID 25832408) and parallel studies in Danish, Spanish, and German cohorts (PMIDs 25832410, 25832411) found no significant association for V232M in large French and multi-European LOAD samples. A European early-onset AD consortium (PMID 26411346; N=2,735) similarly found no enrichment. The V232M variant was consequently reclassified in ClinVar to uncertain significance.

A meta-analysis by Zhang et al. (2016)⁷⁷ meta-analysis by Zhang et al. (2016)
~40,000 subjects across all available datasets arrived at a pooled OR of 1.53, smaller than the discovery estimate but still above unity. The most likely explanation for the instability is statistical: with a carrier frequency of ~0.5–1% and an OR of ~1.5–2, reliably detecting this signal requires tens of thousands of participants — the replication cohorts of 2,000–4,000 each were simply underpowered.

The evidence level is rated moderate: the functional data are consistent and mechanistically compelling, but the population-genetic replication is incomplete and the variant is classified as uncertain significance in ClinVar.

Practical Actions

For carriers of V232M, the relevant lever is the endolysosomal pathway. Aerobic exercise activates TFEB⁸⁸ TFEB
transcription factor EB — the master regulator of lysosomal biogenesis; activated by aerobic exercise via AMPK signalling, which drives synthesis of new, functional lysosomes and partially compensates for the endolysosomal deficit. Sleep quality directly affects glymphatic Aβ clearance — a functionally distinct but complementary route for amyloid removal. Plasma p-tau217 is now a validated blood test for preclinical amyloid accumulation and provides an evidence-based monitoring entry point.

Interactions

APOE ε4 (rs429358) is the dominant genetic risk factor for late-onset AD and operates through partially overlapping mechanisms — disrupting endolysosomal lipid trafficking and reducing microglial amyloid clearance. Carriers of both V232M and APOE ε4 face compounding dysfunction at the endolysosomal level that has not been formally quantified but is mechanistically plausible. TREM2 rare variants (including rs75932628 R47H) converge on microglial lysosomal function and represent a second interaction of interest. ABCA7 variants (rs113809142) also affect endolysosomal lipid transport and amyloid processing in the same compartment.